Biohaven financials
$13.29+0.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$124.9M | -$130.4M | -$142.7M | -$169.4M | -$211.7M | -$221.6M | -$189.9M | -$178.2M | -$333.8M | -$183.2M | -$153.7M | -$110.5M |
| Net income | -$137.3M | -$130.5M | -$145.6M | -$173.4M | -$198.1M | -$221.7M | -$186.8M | -$160.3M | -$319.8M | -$179.5M | -$144.8M | -$102.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.91 | $-0.88 | $-1.21 | $-1.64 | $-1.94 | $-2.17 | $-1.85 | $-1.70 | $-3.64 | $-2.20 | $-1.81 | $-1.50 |
| EBITDA | -$122.6M | -$128.1M | -$140.2M | -$166.3M | -$209.7M | -$219.3M | -$187.5M | -$176.2M | -$331.8M | -$181.8M | -$153.7M | -$109.0M |
| Operating cash flow | -$85.1M | -$149.9M | -$130.7M | -$145.7M | -$167.9M | -$165.1M | -$170.7M | -$141.3M | -$167.8M | -$102.6M | -$114.9M | -$94.8M |
| Free cash flow | -$85.6M | -$149.9M | -$130.7M | -$145.7M | -$168.2M | -$165.6M | -$170.8M | -$141.9M | -$170.7M | -$103.1M | -$115.4M | -$96.1M |
| Diluted shares | 150.6M | 147.6M | 120.4M | 105.8M | 102.4M | 101.9M | 101.2M | 94.4M | 87.8M | 81.6M | 80.0M | 68.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $238.0M | $273.1M | $230.0M | $184.8M | $165.8M | $98.4M |
| Short-term investments | $29.8M | $74.7M | $89.2M | $75.4M | $239.2M | $224.3M |
| Total debt | $259.5M | $241.9M | $238.9M | $268.3M | $257.1M | $0.00 |
| Total assets | $370.7M | $466.4M | $451.4M | $409.1M | $550.4M | $458.9M |
| Total liabilities | $358.5M | $336.9M | $399.4M | $426.3M | $415.8M | $199.5M |
| Shareholders' equity | $12.2M | $129.5M | $52.1M | -$17.2M | $134.6M | $259.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology